Research & Clinical Trials
GenFleet Begins Dosing in China and Australia for GFH276 Pancreatic Cancer Combination Trial
By News Desk ·
Key takeaways
- GenFleet Therapeutics announced initial dosing in China and Australia for its Phase Ib/II GFH276 combination trial on November 16, 2026.
- Phase II will evaluate three first-line pancreatic cancer combinations: GFH276 with cetuximab, AG chemotherapy or mFOLFIRINOX chemotherapy.
- Monotherapy results presented at ESMO showed tumor responses in previously treated pancreatic cancer with no dose-limiting toxicities.
GenFleet Therapeutics announced initial dosing in China and Australia for its Phase Ib/II GFH276 combination trial on November 16, 2026, according to The future of trading. The study will assess the oral pan-RAS inhibitor's safety and efficacy in patients with RAS-mutant pancreatic cancer and solid tumors.
How the GFH276 Combination Trial Is Designed
Phase II will evaluate three first-line pancreatic cancer combinations: GFH276 with cetuximab, AG chemotherapy or mFOLFIRINOX chemotherapy. The trial is testing the pan-RAS inhibitor in RAS-mutant pancreatic cancer and solid tumors.
Monotherapy results already presented at this year's ESMO meeting showed tumor responses in previously treated pancreatic cancer, with no dose-limiting toxicities observed. Preclinical findings already presented at this year's AACR meeting showed enhanced antitumor activity when GFH276 was combined with standard treatments.
GenFleet Therapeutics is a Shanghai-based biotech founded in 2017 that listed on the Hong Kong Stock Exchange in September 2025 under the Chapter 18A framework, raising approximately $268 million with greenshoe and a $100 million cornerstone investment, according to akta.pro company records. The company's leadership includes co-founder and chairman Qiang Lu and co-founder and CEO Jiong Lan.
GenFleet's Earlier GFH276 Results
GenFleet presented initial Phase Ia results for GFH276 at the ESMO annual meeting on October 25, 2026, showing a 41.1% response rate in early-stage pancreatic cancer with favorable safety and manageable side effects, The future of trading reported. On September 18, the National Medical Products Administration placed GenFleet's GFH375 combined with cetuximab on its proposed breakthrough therapy designation list, the same outlet reported.
In January 2025, Verastem Oncology exercised its option for GFH375/VS-7375, an oral KRAS G12D inhibitor, acquiring global development and commercialization rights outside Greater China and launching the registration-directed TARGET-D Phase 2 program in PDAC, NSCLC and CRC, according to akta.pro funding records. GenFleet and Verastem entered an exclusive license and early-stage co-development agreement for three product candidates including GFH375 in August 2023.
What Comes Next for the GFH276 Program
The Phase Ib/II trial will continue assessing GFH276 combinations in RAS-mutant pancreatic cancer and solid tumors across sites in China and Australia. Phase II will evaluate the three first-line combinations with cetuximab, AG chemotherapy and mFOLFIRINOX chemotherapy.